Tharimmune Inc. (THAR) - Total Liabilities
Based on the latest financial reports, Tharimmune Inc. (THAR) has total liabilities worth $1.54 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Tharimmune Inc. (THAR) cash conversion ratio to assess how effectively this company generates cash.
Tharimmune Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Tharimmune Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Tharimmune Inc. (THAR) shareholders funds for net asset value and shareholders' equity analysis.
Tharimmune Inc. Competitors by Total Liabilities
The table below lists competitors of Tharimmune Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Innate Pharma
PA:IPH
|
France | €87.79 Million |
|
Kenorland Minerals Ltd
V:KLD
|
Canada | CA$13.21 Million |
|
Coda Octopus Group Inc
NASDAQ:CODA
|
USA | $5.44 Million |
|
Hooker Furniture Corporation
NASDAQ:HOFT
|
USA | $70.48 Million |
|
Shanghai Jinjiang International Travel Co Ltd
SHG:900929
|
China | $532.93 Million |
|
Companhia Estadual de Distribuição de Energia Elétrica
SA:CEED3
|
Brazil | R$12.96 Billion |
|
Horizon Copper Corp.
V:HCU
|
Canada | CA$610.65 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Tharimmune Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see THAR stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tharimmune Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tharimmune Inc. (2019–2024)
The table below shows the annual total liabilities of Tharimmune Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.41 Million | +33.00% |
| 2023-12-31 | $1.82 Million | +58.52% |
| 2022-12-31 | $1.14 Million | -78.42% |
| 2021-12-31 | $5.31 Million | +32.26% |
| 2020-12-31 | $4.01 Million | +141.26% |
| 2019-12-31 | $1.66 Million | -- |
About Tharimmune Inc.
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. w… Read more